Reolysin

Oncolytics Biotech Inc. is a pharmaceutical company focused on developing an oncolytic virus, REOLYSIN, for the treatment of cancers. REOLYSIN contains a reovirus that selectively replicates in Ras activated tumor cells. Interim results from ongoing clinical trials show promising signs of efficacy including durable responses. Oncolytics' clinical program includes 10 active trials of REOLYSIN as a monotherapy and in combination with chemotherapy. The company has a strong intellectual property portfolio and is working to produce REOLYSIN at commercial scale.